Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”) disclosed that it repurchased 1.30 million H-shares on 15 September 2026 via on-market transactions on the Hong Kong Stock Exchange. The shares were bought at prices ranging from HKD 16.89 to HKD 17.10, with a volume-weighted average cost of HKD 16.98 per share, bringing the aggregate consideration to HKD 22.07 million.

Following the transaction, Fosun Pharma’s issued share capital (excluding treasury shares) fell to 534.81 million, down 0.24% from 536.11 million on 14 September 2026. The company’s treasury share balance increased from 15.83 million to 17.13 million shares, while total issued shares remained unchanged at 551.94 million, as the repurchased shares are being held in treasury and have not yet been cancelled.

The buyback forms part of the repurchase mandate approved on 16 June 2026, which authorises the company to purchase up to 54.10 million shares. Including the latest transaction, Fosun Pharma has repurchased 6.16 million shares under this mandate, representing 1.14% of the company’s issued shares at the mandate date, leaving significant headroom for further repurchases.

Under Hong Kong listing rules, Fosun Pharma is subject to a moratorium on issuing new shares or disposing of treasury shares until 15 October 2026.